Original Research Article

Diphtheria: a re-emerging infectious disease

Shashidhar S. Suligavi1, Divya K. Vishwanath1*, Shilpa Gokale2, S. S. Doddamani1

1Department of ENT, 2Department of Microbiology, S. Nijalingappa Medical College, Bagalkot, Karnataka, India

Received: 19 December 2020
Revised: 20 January 2021
Accepted: 21 January 2021

*Correspondence:
Dr. Divya K. Vishwanath,
E-mail: divyavishwanathk@gmail.com

ABSTRACT

Background: Diphtheria is a fatal bacterial infection which affects the mucous membranes of oropharyngeal and nasal cavity, caused by aerobic gram-positive bacteria Corynebacterium diphtheriae. Clinical diphtheria is on the increase worldwide, mainly affecting developing countries and leading cause of morbidity and mortality. We sought to understand its presentation among patients and also early intervention of the disease. The objective of the study was to study the clinico-demographic profile of cases, the relationship between immunization status and clinical disease, the role of microbiological investigations and to identify complications in diphtheria cases.

Methods: This study is a hospital based observational study from September 2019 - September 2020 at a tertiary care centre, S.Nijalingappa Medical College and HSK hospital, Bagalkot, Karnataka. The cases were analysed with respect to demographic details, clinical features, immunization status, microbiological confirmation and complications of diphtheria cases.

Results: 32 cases were suspected to have diphtheria on clinical examination. The mean age of presentation was 15 years. Fever, sore throat, difficulty in swallowing, neck swelling and pseudomembrane in oral cavity were the common signs and symptoms. Airway compromise, myocarditis and neurological complications were noted. Antidiphtheritic serum (ADS) was tried in all 32 cases and 8 cases had adverse reactions. Case fatality rate was 12.5%.

Conclusions: Shifting of occurrence of diphtheria in the age group of ≥5 years suggest the need to improve and strengthen the immunization program specially the booster doses.

Keywords: Diphtheria, Antidiphtheritic serum, Albert stain, Myocarditis

INTRODUCTION

Diphtheria is an infectious disease caused by the exotoxin produced by Corynebacterium diphtheriae.1 The organisms are locally invasive and secrete soluble exotoxins, which can lead to serious consequences mainly involving the heart muscle and nervous system. Death can occur due to circulatory failure within the first 10 days of infection.2 If diagnosed early, the infection responds to appropriate antibiotics and prompt antitoxin therapy.

The incidence of diphtheria is high in India, especially in the region of North Karnataka. Factors contributing to morbidity and mortality include patient’s immunization status, age at infection, time of infection, clinical type, and time of intervention.3 An accurate microbiological diagnosis of diphtheria is crucial and is always regarded as being complementary to clinical diagnosis because diphtheria is often confused with other conditions, such as severe streptococcal sore throat, Vincent’s angina, or glandular fever.4
As per World health organization (WHO) data from 2000 to 2016, over 82% of diphtheria cases occurred in children above 5 years and over 40% occurred in individuals over 15 years of age. This second shift is due to the waning immunity as the child grows older and is the reason why regular booster doses are recommended. India has the maximum number of diphtheria cases in the world, from 2011 to 2015 India had a total of 18,350 cases of diphtheria. Over 40% of cases reported in India are from individuals over 15 years and about 20% cases are reported from children under the age of 5 years.

Aims and objectives

To study the clinico-demographic presentation of diphtheria cases. To know the immunization status in diphtheria cases. To know the role of microbiological investigations in diphtheria cases. To identify the complications in diphtheria cases.

METHODS

Place of study

S. Nijalingappa Medical College and HSK Hospital.

Study population

All cases with clinical suspicion of diphtheria admitted in HSK hospital.

Exclusion criteria

Patient who already treated with antibiotic prior throat swab

Study period

September 2019 to September 2020.

Type of study

Observational case series study.

The following data were recorded: age, sex, clinical symptoms and signs. Patients were categorized into four age groups: <5, 5–20, 20–40 and >40 years. Immunization status was documented as per the information given by the parents/patients. Those who had received three primary doses at 4-6 weeks interval starting at 6 weeks of age, followed by booster doses at 18 months and 5 years were recorded as “Immunized”. Those who had not received any doses and not known immunization status were considered as “Unimmunized”/“Unknown status”. Patients who had missed one or more of the three primary doses or booster doses were included as “Partially immunized”.

Microbiological investigations

Sample collection

Under aseptic precautions, two throat swabs were taken from all suspected cases of diphtheria. Swabs should be collected underneath the pseudomembrane or a piece of membrane should be removed. One swab was used for direct microscopy and the other for culture.

Table 1: Paediatric and Adult ADS (antidiphtheritic serum) dose.

| Diphtheria clinical presentation                                      | ADS dose in IU (# of ampoules) |
|--------------------------------------------------------------------|--------------------------------|
| Pharyngeal or laryngeal disease of 2 days duration                 | 20000–40000 (2-4)              |
| Nasopharyngeal disease                                             | 40000–60000 (4-6)              |
| Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck | 80000–100000 (8-10)            |
| Skin lesions only (rare case)                                      | 20000–40000 (2-4)              |

Direct microscopy

Gram staining and Albert staining of swab smears were carried out.

Culture and sensitivity

Throat swab was inoculated on blood agar, Mc conkey agar and Potassium tellurite agar. Growth after 24-72hr incubation was identified using standard methods.

Toxigenicity testing

The isolates confirmed by biochemical reaction was sent to CMC vellore for PCR test and it detects the tox-bearing gene.

All the patients registered under the study were given appropriate antibiotics and antidiphtheritic serum (ADS).
Desensitization was done in case of adverse reaction to ADS such as rashes, hypotension, serum sickness etc.

\[
\text{1 ml (antitoxin)} + 9.0 \text{ ml saline} = 1:10 \text{ dilution}
\]

\[
\text{1 ml (1:10 dilution)} + 9.0 \text{ ml saline} = 1:100 \text{ dilution}
\]

\[
0.1 \text{ ml (1:10 diution)} + 9.9 \text{ ml saline} = 1:1000 \text{ dilution}
\]

\[
\text{1 ml (1:100 dilution)} + 9 \text{ ml saline} = 1:1000 \text{ dilution}
\]

**Table 2: Desensitization to ADS- intravenous route.**

| Dose number | Dilution of ADS in normal saline | Amount of injection(cc) |
|-------------|---------------------------------|-------------------------|
| 1           | 1:1000                          | 0.1                     |
| 2           | 1:1000                          | 0.3                     |
| 3           | 1:1000                          | 0.6                     |
| 4           | 1:100                           | 0.1                     |
| 5           | 1:100                           | 0.3                     |
| 6           | 1:100                           | 0.6                     |
| 7           | 1:10                            | 0.1                     |
| 8           | 1:10                            | 0.3                     |
| 9           | 1:10                            | 0.6                     |
| 10          | undiluted                       | 0.1                     |
| 11          | undiluted                       | 0.2                     |
| 12          | undiluted                       | 0.6                     |
| 13          | Undiluted                       | 1.0                     |

Administer at 15 minute intervals.

**RESULTS**

Out of 32 patients, 2 patients (6.2%) were less than 5 years age group, 24 patients (75%) were between 5-20 years and 6 patients (18.8%) were above 20 years. Paediatric age group - 21 cases; adults - 11 cases. 16 patients (50%) were males and 16 (50%) were females.

**Table 3: Age distribution.**

| Age group (years) | Number of patients (%) |
|-------------------|------------------------|
| >5                | 2 (6.2)                |
| 5-20              | 24 (75)                |
| 20-40             | 5 (15.5)               |
| >40               | 1 (3.3)                |
| Total             | 32 (100)               |

**Immunization status**

9 (28.1%) were fully immunized and 17 (53.2%) were partially immunized and 6 (18.7%) were unimmunized/unknown status.

**Bull neck**

Out of 32 patients, 19 (59.3%) presented with bull neck at presentation.

**Table 4: Immunization status.**

| Immunization status                  | Number of patients (%) |
|--------------------------------------|------------------------|
| Fully immunized                      | 9 (28.1)               |
| Partially immunized                  | 17 (53.2)              |
| Unimmunized/ Unknown status          | 6 (18.7)               |
| Total                                | 32 (100)               |

**Table 5: Clinical presentation.**

| Clinical presentation              | Number of patients (%) |
|------------------------------------|------------------------|
| Fever                              | 32 (100)               |
| Throat pain                        | 32 (100)               |
| Cough                              | 18 (56.25)             |
| Bull neck swelling                 | 19 (59.3)              |
| Dysphagia                          | 12 (37.5)              |
| Epistaxis                          | 1 (3.12)               |

**Table 6: Microbiological investigations.**

| Lab parameter                      | Data (%)              |
|------------------------------------|-----------------------|
| Albert stain                       | 18 (56.2)             |
| Positive                           | 14 (43.7)             |
| Throat swab culture                | Positive, 21 (65.6)   |
| Negative                           | Negative, 11 (34.3)   |

**Myocarditis**

Out of 32 patients, 12 (37.5%) developed myocarditis and 4 (12.5%) patients died.

**Microbiological investigations**

Albert staining was performed in 32 cases of which 18 (56.2%) were positive. Culture was performed in 32 cases of which 21 were positive (65.6%). In our study 20 isolates were found to be toxigenic and 1 isolates was contaminated in the transportation and toxigenicity testing was not done for that isolate.

![Figure 1: ADS adverse reaction- rashes over legs.](image-url)
Antidiphtheritic serum (ADS) administration

ADS was administered in all 32 cases out of which 8 patients developed ADS reaction and desensitization was done.

DISCUSSION

In the pre-vaccine era, disease was common among children less than 5 years of age due to natural boost to the development and maintenance of immunity in adolescence and adults. However, after widespread immunization in children, lack of or inadequate booster doses in children and adult and decrease incidence of cutaneous diphtheria, there is shift of age for the occurrence of disease in older children and adults. Such a shifting of age of occurrence was observed in developed and developing countries including India.8

In present study 93.8% patients were more than 5 years of age (Table 3). However, Meshram et al (55.32%) Basavaraja et al (74.1%), Bandichhode et al (66.66%) also reported resurgence of disease in children of more than 5 years of age.9,11

Factors contributing to the low immunization coverage include lack of awareness, misconception, avoiding immunization for trivial reasons, migration, decline in enthusiasm to routine immunization, unilateral focus on pulse polio campaign, short supply of vaccine, not maintaining proper storage of vaccine (cold chain), poor clinic organization, non-availability of immunization services on all day of week, not opening a multidose vial if enough children are not present and delaying or postponing vaccination in minor childhood illness.15

In present study, 9 (28.1%) patients were fully immunized, 17 (53.2%) were partially immunized and 6 (18.7%) were unimmunized/unknown status (Table 4). This denotes unsatisfactory immunization coverage with DT/DPT (Diphtheria, Pertussis and Tetanus) vaccine in respective rural area.

The clinical manifestation can vary from mild to severe to the life threatening depending on immune status of host and severity of infection. All patients presented with fever, pseudomembrane in throat and throat pain (100%) followed by bull neck 19 (59.3%), dysphagia 12 (37.5%), epistaxis 1 (3.2%) (Table 5). Similar clinical details were reported by various authors from various parts of India. Cases of diphtheria were seen throughout the year but more number of cases was observed during month of June to September during rainy season. Some authors reported peak during the winter season and some in rainy season.11,16

In our study Albert stain was positive in 18 cases (56.2%) and growth in culture was seen in 21 cases (65.6%) out of 32 tested (Table 6). False negative reports are seen because of prior antibiotic use, difficulties in proper throat swab collection due to lymphadenopathy, bull neck and delayed transportation of sample to the laboratory. Low Corynebacterium yield were reported by Basavaraja
et al (16.1%), Bandichhode et al (33.33%), Singh et al (30.63%).

Myocarditis was the commonest complication 12 (37.5%) followed by palatal palsy 3 (9.3%), airway obstruction 2 (6.2%). Case fatality rate was 12.5% and cause of death was cardiopulmonary arrest. In India, incidence of diphtheric myocarditis varies from 16 to 66% because toxin-mediated inhibition of protein synthesis is known to be the essential mechanism of all complications of diphtheria, especially myocarditis, as the exotoxin is directly cardiotoxic and can cause DNA fragmentation and cytolysis by inhibiting elongation factor-2 activity in protein synthesis leading to tissue damage.9,17,18

Palatal palsy was characterized by a nasal quality of voice, nasal regurgitation commonly occurring in second and third week and is the earliest neurological complication which may occur alone or in association with other types of paralysis. However in Meshram et al study, 7 (14.89%) patients had palatal palsy and 4 (8.51%) had polyneuropathy with or without cranial nerve involvement.9

In present study we analyzed all the cases of diphtheria hospitalized in S N Medical College from a period of September 2019 to September 2020. Data collected showed mean age of affected is 15 years. In present study, 32 cases (100%) were found to have a pseudo membrane. Authors consider a pharyngeal membrane that is difficult to peel off and leaves a bleeding area on the mucous membrane after an attempt to remove it pathognomonic for diphtheria. All patients were treated with anti-diphtheritic serum as recommended by WHO and UNICEF. The most commonly administered antibiotics were penicillin or erythromycin following recommendations of the WHO and UNICEF. Every patient in present study had a throat swab taken and 65.6% of cases had microbiologically confirmed disease. There was 12.5% mortality in present study and one patient was COVID positive. This observation suggests that complete vaccination is essential in preventing fatalities. Diphtheria is still not a lost entity as cases are coming to tertiary care level. Immunization activity needs to be improved and strengthened in borderline districts as well as close monitoring for development of complications are key factors in successful management of individual cases. Therefore, serious efforts have to be made to increase immunization coverage and good surveillance systems ought to be put into place to enable optimum reporting of disease.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. Dikid T, Jain SK, Sharma A, Kumar A, Narain JP. Emerging and re-emerging infections in India: an overview. Indian J Med Res. 2013;138:19-31.
2. Government of India. Annual report 2012. India: Ministry of Health. 2012.
3. Meera M, Rajarao M. Diphtheria in Andhra Pradesh—a clinical—epidemiological study. Int J Infect Dis. 2014;19:74-78.
4. Efstratiou A, Engler KH, Mazurova IK, Glushkevich T, Vuopio-Varkila J, Popovic, T. Current approaches to the laboratory diagnosis of diphtheria. J Infect Dis. 2000;181:S138-45.
5. Clarke KEN. Review of the Epidemiology of Diphtheria (2000-2016). US Centers for Disease Control and Prevention.
6. World Health Organization. Diphtheria vaccine: WHO position paper, August 2017-Recommendations. Vaccine. 2018;36(2):199-201.
7. World Health Organisation. WHO vaccine preventable diseases: monitoring system 2017 global summary.
8. Ujwal MV, Pol RR, Vanaki R, Yelamali BC, Badakali AV. Resurgence of diphtheria in rural north Karnataka: Clinical profile and outcome. International journal of Medical Paediatrics and Oncology. 2019;5(1).
9. Meshram RM, Patil A. Clinical profile and outcome of diphtheria in central India: a retrospective observational. Study Int J Contemp Pediatr. 2018;5(4):1600-605.
10. Basavaraja GV, Chebbi PG, Joshi S. Resurgence of diphtheria: clinical profile and outcome- a retrospective observational study. Int J of Contemp Pediatr. 2016;3(1):60-63.
11. Bandichhode ST, Jatti GM, Anita MS, Nandimath VA. A clinical study of diphtheria cases in a pediatric population in tertiary care hospital in western Maharashtra. Indian J Child Health. 2016;3(3):251-53.
12. Maheriya KM, Pathak GH, Chauhan AV, Mehariya MK, Agrawal PC. Clinical and epidemiological profile of diphtheria in tertiary care hospital. Gujarat medical J. 2014;89(2):105-8.
13. Singh SN, Singh A, Chandra S. Clinical profile and prediction of poor outcome of hospitalized diphtheria cases in children from Lucknow region of
North India. Clin Epidemiol Glob Health 2014;2:75-9.
14. Sharma NC, Banavaliker JN, Ranjan R, Kumar R. Bacteriological and epidemiological characteristics of diphtheria cases in and around Delhi-a retrospective study. Indian J Med Res. 2007;126(6):545-52.
15. Bairwa M, Rajput M, Sachdeva S. Modified Kuppuswamy’sSocioeconomic scale: Social researcher should include updated income criteria, 2012. Indian J Community Med 2013;38(3):185-86.
16. Siakia L, Nath R, Saikia NJ, Choudhary G, Sarkar M. A diphtheria outbreak in Assam, India. Southeast Asian J Trop Med Public Health. 2010;41:647-52.
17. Verghese MJ, Ramakrishnan SS, Saxsena A. Complete heart block due to diphtheritic myocarditis in the present era. Ann Pediatr Cardiol. 2013;6:34-8.
18. Jayasri M, Shruti N, Singh S. Predictors of outcome in patients with diphtheria receiving intensive care. Indian Pediatr. 2006;43:155-60.

Cite this article as: Suligavi SS, Vishwanath DK, Gokale S, Doddamani SS. Diphtheria: a re-emerging infectious disease. Int J Otorhinolaryngol Head Neck Surg 2021;7:475-80.